Benoit spent over 30 years on growing healthcare businesses and, solving fast growth-related issues as an entrepreneur, advisor and deal maker, or independent board member.
He has an unrivaled experience in pharmaceutical outsourcing. He created and led an advisory firm, a central lab, and a clinical project monitoring unit, the three business units of what became the leading clinical stage CRO in Continental Europe in the late nineties with over 400 people, mainly located in France, Italy, and Germany. He is a board member at Mapi Group, then a late phase CRO with few tens of people and today the world leader in late phase patient-centered research with 800 people and revenues north of €100m.
Benoit has a dual scientific (PharmD Pharmacy 1984; PhD Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education. His professional background enabled him to get to know in details all aspects of a healthcare venture stage company and to favor understanding and collaboration between scientists and business persons.
In the investment banking field, he has been the head of Puilaetco (since acquired by KBC) research team between 1998 and 2002, instrumental in the emergence of a fund investing in innovative healthcare companies and of what became the reference M&A healthcare team in Europe (Bryan Garnier). He sourced and led the execution of over 40 M&A transactions and financing rounds for biotechnology and medical device companies, or CROs. He is an advisor to IMAP, a 400 M&A professionals network with a presence in over 40 countries, ranked since years in the worldwide top 5 Thomson Financials league tables in the small and mid-markets.
Mounia leads NEOMED-LABS’ corporate strategies and development. Prior to joining NEOMED-LABS, she was Director, Scientific Affairs at the NEOMED Institute, responsible for the identification and evaluation of new opportunities to complement NEOMED’s prospecting activities.
Before joining the NEOMED initiative, she was Director of Programs at CQDM, where she was responsible for the evaluation and management of research projects and funding programs. Previously, she was Investment Manager at MSBi Valorization, where she covered all aspects of the valorization and investment process, including identification, evaluation, due diligence, negotiation, and fundraising for opportunities in the life sciences sector. She was also actively involved in business development activities with potential industry partners. She started her career as leader of the cellular biology group at Bellus Health (formerly Neurochem Inc.), where she was involved in the development of therapeutics targeting Alzheimer’s disease and diabetes.
Mounia holds a PhD degree in Neuroscience from Université Pierre et Marie Curie (UPMC) in Paris.
Vahé has 25 years of experience in finance and accounting with the last 15 years in the Pharma/Vaccine industry, mainly as North American Finance Head for GlaxoSmithKline Vaccines (GSK).
He also worked in the technology industry for private & public companies, for startup & global structures in the manufacturing and servicing industries. During his career, Vahé was involved in M&A, integrations, IPO, global transactions, but also in operating responsibilities by leading finance teams. in 2015, he was involved in the creation of NEOMED-LABS by leading the project from the GSK side. He joined NEOMED-LABS as a CFO in August 2017 where he manages the finance functions and supports the strategic growth of the company. Vahé is a CPA-CMA and holds an MBA from HEC Montreal.
Over 25 years of experience in the CRO industry. She filled different positions in different CRO’s. She began as a laboratory / instrument manager (LCMS/MS) at Phoenix International, then she gradually rose through the ranks to Senior Director of Operations at Biotrial Bioanalytical Services (Warnex Inc).
She oversaw the LBA and the LCMS/MS groups, was responsible for the regulatory affairs, headed many FDA, EMA, clients and other agencies audits as well as being involved in the CRO’s industry as a member of the GCC group.